Treatment with CQ and HCQ at the dose between 250-400 mg decreased TC, TG, LDL-C, apolipoprotein B (apoB) and the ratio of apoB to apolipoprotein A-1 (apoA-1) but did not affect non-esterified fatty acids (NEFA) and HDL-C levels in T2DM patients 37,39. The gene discussed is APOB; the disease is type 2 diabetes mellitus.